The Effect of Different Ventilation Modes on the Outcomes of Patients Infected with Coronavirus Disease 2019 (COVID-19): a Protocol of Systematic Review and Network Meta-Analysis

Abstract Background: Coronavirus disease 2019 (COVID-19) outbreak has spread around the world, the high mortality rate and strong infectious cause surging global patients diagnosed patients and death while in response to the outbreak, a myriad of scientific research workers and researchers have made unremitting efforts, but effective treatments are still limited, even may say that there is no specific treatment. So a large number of patients with severe patients need treatment for respiratory support, in particular, based on various realistic factors, different way of ventilation is widely used in clinical, which kind of ventilation way is the best one of the most effective ventilation strategy is not clear, so we planned a network meta-analysis to evaluate different ventilation methods on new crown the efficacy and safety of patients, expect to find an optimal ventilation strategy.Methods and analysis: Two authors will independently search the electronic databases, preprints databases, Clinical Study Registration website and COVID-19 research related project database from December 1, 2019 to November 5, 2020. The primary outcomes are 1) All-cause mortality; 2) Transmission of COVID-19 to health care workers and other people; 3) Length of hospital stay; 4) Length of ICU stay. A systemic review and a network meta-analysis based on Bayesian framework will be performed to assess the effect of different ventilation modes on the outcomes of patients infected with COVID-19. The Grading of Recommendations Assessment, Development and Evaluation System (GRADE) will be used to evaluate the quality of evidence.Discussion: COVID-19 has spread around the world and become a global public health security problem. With limited treatment available, a large number of critically ill patients need ventilator support treatment, and the demand for ventilators has increased sharply. To our knowledge, this study will be the first systematic review and NMA to analyze the efficacy and safety of different ventilation modes in patients with COVID-19. This study expected to obtain the best choice of ventilation mode for COVID-19 patients based on high quality evidence. Ethics and dissemination: Ethical approval is not required owning to it is a literature-based study. The final conclusion will be disseminated through peer-reviewed publication. PROSPERO registration number: CRD42020219581

Download Full-text

The efficacy and safety of interferons for the treatment of patients with COVID-19: protocol for systematic review and meta-analysis of controlled trials

Health Technology Assessment in Action ◽

10.18502/htaa.v4i3.6347 ◽

2021 ◽

Author(s):

Afsaneh Noormandi ◽

Mohammad Fathalipour ◽

Reza Daryabeygi-Khotbehsara ◽

Soheil Hassanipour

Keyword(s):

Systematic Review ◽

Clinical Trials ◽

Meta Analysis ◽

World Health ◽

Controlled Trials ◽

Efficacy And Safety ◽

Global Pandemic ◽

The World ◽

Health Organization ◽

Time Of Administration

Background and objective: COVID-19 has since been declared a global pandemic by the World Health Organization (WHO), infecting millions worldwide. The use of Interferon (INF) subtypes previously examined in the treatment of SARS and MERS is also being initiated in some clinical trials. Although different clinical trials were evaluated IFNs in the treatment of COVID-19, their efficacy and safety remain unknown. Therefore, this study aims to systematically assess IFNs efficacy and safety in treating patients with COVID-19. Methods: The protocol has been registered in the PROSPERO International Prospective Register (CRD42020200643) on 24 July 2020. This protocol has been arranged according to the PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols) 2015 checklist. Discussion: Due to lack of approved medication for the covid-19 treatment and also various mutations of this virus, evaluated the efficacy and safety of medications by various studies could help for finding treatments with high effectiveness. IFNs are one of the medications that have been administered in covid-19 infection. Moreover, the best time of administration and dose of this medication was unknown. Although meta-analysis is a potent source for assessing the accuracy of subjects, heterogeneity of articles is a potent limitation of our work.

Download Full-text

Comparative Efficacy and Safety of the Moxibustion for the Treatment of Coronavirus Disease 2019 (COVID-19): Protocol for a Systematic Review and Meta-analysis.

10.21203/rs.3.rs-442162/v1 ◽

2021 ◽

Author(s):

Juan Gao ◽

Xiujuan Zhou ◽

Hongyan Xie ◽

hong Gao ◽

xiaoxu Fu ◽

...

Keyword(s):

Systematic Review ◽

Clinical Symptoms ◽

Meta Analysis ◽

Efficacy And Safety ◽

Eligibility Criteria ◽

Manual Search ◽

Acute Respiratory Insufficiency ◽

The World ◽

Complementary And Alternative

Abstract Background Coronavirus disease 2019 (COVID-19) has spread from its origins to the world and become a pandemic since late 2019. It predominantly damages the lungs and causes diffuse alveolar injury with edema, cellular fibroblasts and hyaline membrane formation, resulting in acute respiratory insufficiency, respiratory failure, sepsis, acute heart injury, heart failure and other severe complications. It is also reported that moxibustion can effectively modify the negative emotions and relieve the symptoms of chest distress and impaired appetite for the patient with COVID-19. The main objective of current research is to make an assessment for effectiveness and safety of the moxibustion as an important complementary and alternative therapeutic method for COVID-19.Methods and analysis Articles for the systematic literature will be located at the MEDLINE, OVID, EMBASE, CNKI, CBM, NTR, Chi CTR databases. With no restriction about language, manual search will be conducted for potential eligible articles as supplements. Any randomized controlled trials (RCTs) with any moxibustion interventions issued by the therapeutic regimen on all patients diagnosed with COVID-19 will be included. We will include the published studies with no restriction about language. All study records of the title and abstract identified by the search strategies will be directly imported and assessed based on the eligibility criteria. Risk of individual studies for the methodological quality of eligible RCTs will be assessed with the tool from the Cochrane Collaboration’s risk of bias tool.Discussion The purpose of this study is to conduct a systematic review and meta-analysis of the efficacy and safety of moxibustion as a complementary and alternative treatment for COVID-19.No studies have investigated whether moxibustion will relieve clinical symptoms and shorten the length of hospitalization time.To the best of our knowledge, this is the first systematic review and meta-analysis program designed to update the currently available evidence. Despite the fact of controversial views in using moxibustion, if this study confirms its efficacy and safety, it could provide a better guide for clinical practice around the world.Systematic review registrationPROSPERO CRD42020176572.

Download Full-text

Efficacy and Safety of Mycophenolate Mofetil Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-Analysis

10.21203/rs.3.rs-38802/v1 ◽

2020 ◽

Author(s):

Sakdipat Songwisit ◽

Punchika Kosiyakul ◽

Jiraporn Jitprapaikulsan ◽

Naraporn Prayoonwiwat ◽

Patompong Ungprasert ◽

...

Keyword(s):

Systematic Review ◽

Mycophenolate Mofetil ◽

Disease Severity ◽

Relapse Rate ◽

Neuromyelitis Optica ◽

Meta Analysis ◽

Neuromyelitis Optica Spectrum Disorders ◽

Efficacy And Safety ◽

Number Of Patients ◽

Spectrum Disorders

Abstract Background: Neuromyelitis optica spectrum disorders (NMOSD) is an autoimmune demyelinating disease of the central nervous system characterized by severe attacks of optic nerve and spinal cord. Mycophenolate mofetil (MMF) is an immunosuppressive agent (IS) which is widely prescribed for NMOSD patients. This systematic review and meta-analysis aims to assess the efficacy and safety of MMF in controlling relapse and disease severity.Methods: Studies were obtained from the EMBASE and Ovid MEDLINE databases. Eligible studies were the studies of NMOSD patients treated with MMF which reported treatment outcomes as Annualized Relapse Rate (ARR) or Expanded Disability Status Scale (EDSS) before and after treatment. Case reports, case series less than 3 patients, and reviews were excluded.Results: Fifteen studies included 1047 patients, of whom 915 (87.4%) were aquaporin-4 immunoglobulin seropositive. The total number of patients that received MMF was 799. Meta-analysis on ARR and EDSS were conducted in 4 studies with a total of 200 patients and 3 studies with a total of 158 patients, respectively. The result showed a significant improvement with a mean reduction of 1.13 (95% confidence interval (CI), 0.60 to 1.65) in ARR and a mean reduction of 0.85 (95% CI, 0.36 to 1.34) in EDSS after MMF therapy. Adverse drug reactions occurred in 106 (17.8%) of 594 patients that were documented having side effects during MMF therapy.Conclusion: This systematic review and meta-analysis showed that using MMF as a preventive therapy in NMOSD patients can significantly reduce relapse rate and improve disease severity with an acceptable tolerability.

Download Full-text

Comparative efficacy and safety of current drugs against COVID-19: A systematic review and network meta-analysis

10.1101/2020.11.16.20232884 ◽

2020 ◽

Author(s):

Yi Li ◽

Wei He

Keyword(s):

Systematic Review ◽

Clinical Evidence ◽

Meta Analysis ◽

Clinical Decision ◽

Added Value ◽

Efficacy And Safety ◽

Outcome Indicators ◽

Rapid Spread ◽

The World ◽

Significant Health

AbstractThe rapid spread of coronavirus disease (COVID-19) has greatly disrupted the livelihood of many people around the world. To date, more than 35.16 million COVID-19 cases with 1.037million total deaths have been reported worldwide. Compared with China, where the disease was first reported, cases of COVID-19, the number of confirmed cases for the disease in the rest of the world have been incredibly high. Even though several dugs have been suggested to be used against the disease, the said interventions should be backed by empirical clinical evidence. Therefore, this paper provides a systematic review and a meta-analysis of efficacy and safety of different COVID-19 drugs.Research in contextEvidence before this studyCurrently, Covid-19 is one of the most urgent and significant health challenge, globally. However, so far there is no specific and effective treatment strategy against the disease. Nonetheless, there are numerous debates over the effectiveness and potential adverse effects of different COVID-19 antivirals. In general, there is invaluable need to continually report on new advances and successes against COVID-19, apparently to aid in managing the pandemic.Added value of this studyThis study provides a comprehensive, evidence-based guide on the management of multiple COVID-19 symptoms. In particular, we provide a review of 14 drugs, placebos and standard treatments against COVID 19. Meanwhile, we also performed a meta-analysis based on four clinical outcome indicators, to measure and compare the efficacy and safety of current interventions.Implications of all the available evidenceFindings of this research will guide clinical decision in COVID-19 patients. It will also provide a basis for predicting clinical outcomes such as efficacy, mortality and safety of interventions against the disease.

Download Full-text

Efficacy and safety of endovascular arteriovenous fistula creation with comparison to surgically created fistulas: a systematic review and meta-analysis protocol v2

10.17504/protocols.io.bu95nz86 ◽

2021 ◽

Author(s):

Yoshinosuke Shimamura ◽

Hajime Yamazaki ◽

Takamasa Miyauchi ◽

Hiroshi Ueta ◽

Yasutaka Kuniyoshi ◽

...

Keyword(s):

Systematic Review ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Arteriovenous Fistula ◽

Clinical Efficacy ◽

Meta Analysis ◽

Systemic Review ◽

Efficacy And Safety ◽

Analysis Protocol

This systemic review and meta-analysis aimed to evaluated existing evidence on the clinical efficacy and safety of endovascular arteriovenous fistula creation by directly comparing it with surgical arteriovenous fistula creation among patients with chronic kidney disease requiring hemodialysis.

Download Full-text

Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis

Scientific Reports ◽

10.1038/s41598-020-73882-8 ◽

2020 ◽

Vol 10 (1) ◽

Author(s):

Sakdipat Songwisit ◽

Punchika Kosiyakul ◽

Jiraporn Jitprapaikulsan ◽

Naraporn Prayoonwiwat ◽

Patompong Ungprasert ◽

...

Keyword(s):

Systematic Review ◽

Mycophenolate Mofetil ◽

Disease Severity ◽

Neuromyelitis Optica ◽

Meta Analysis ◽

Immunosuppressive Agent ◽

Preventive Therapy ◽

Efficacy And Safety ◽

Number Of Patients ◽

Before And After

Abstract Mycophenolate mofetil (MMF) is an immunosuppressive agent (IS) which is widely prescribed in neuromyelitis optica spectrum disorder (NMOSD) patients. We aim to assess the efficacy and safety of MMF in controlling relapse and disease severity. Eligible studies obtained from the EMBASE and Ovid MEDLINE databases were studies of NMOSD patients treated with MMF, which reported treatment outcomes as Annualized Relapse Rate (ARR) or Expanded Disability Status Scale (EDSS) before and after treatment. Fifteen studies included 1047 patients, of whom 915 (87.4%) were aquaporin-4 immunoglobulin seropositive. The total number of patients that received MMF was 799. A meta-analysis on ARR was conducted in 200 patients from 4 studies and on EDSS in 158 patients from 3 studies. The result showed a significant improvement with a mean reduction of 1.13 [95% confidence interval (CI) 0.60–1.65] in ARR, and a mean reduction of 0.85 (95% CI 0.36–1.34) in EDSS after MMF therapy. Adverse events occurred in 106 (17.8%) of 594 patients during MMF therapy. This systematic review and meta-analysis showed that using MMF as a preventive therapy in NMOSD patients can significantly reduce relapse rates and improve disease severity with acceptable tolerability.

Download Full-text

Efficacy and safety of mesenchymal stem cells for the treatment of patients infected with COVID-19: a systematic review and meta-analysis protocol

BMJ Open ◽

10.1136/bmjopen-2020-042085 ◽

2020 ◽

Vol 10 (12) ◽

pp. e042085

Author(s):

Yunhui Chen ◽

Qing Zhang ◽

Wei Peng ◽

Dan Liu ◽

Yanyan You ◽

...

Keyword(s):

Systematic Review ◽

Evaluation System ◽

Meta Analysis ◽

Case Series ◽

Biomedical Literature ◽

Cochrane Library ◽

Controlled Trials ◽

Progression Rate ◽

Efficacy And Safety ◽

Promising Therapeutic Approach

IntroductionTo date, no specific antivirus drugs or vaccines have been available to prevent or treat the COVID-19 pandemic. Mesenchymal stem cell (MSC) therapy may be a promising therapeutic approach that reduces the high mortality in critical cases. This protocol is proposed for a systematic review and meta-analysis that aims to evaluate the efficacy and safety of MSC therapy on patients with COVID-19.Methods and analysisTen databases including PubMed, EMBASE, Cochrane Library, CINAHL, Web of Science, Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), Wanfang database, China Biomedical Literature Database (CBM) and Chinese Biomedical Literature Service System (SinoMed) will be searched from inception to 1 December 2020. All published randomised controlled trials, clinical controlled trials and case series that meet the prespecified eligibility criteria will be included. The primary outcomes include mortality, incidence and severity of adverse events, respiratory improvement, days from ventilator, duration of fever, progression rate from mild or moderate to severe, improvement of such serious symptoms as difficulty breathing or shortness of breath, chest pain or pressure, and loss of speech or movement, biomarkers of laboratory examination and changes in CT. The secondary outcomes include dexamethasone doses and quality of life. Two reviewers will independently perform study selection, data extraction and assessment of bias risk. Data synthesis will be conducted using RevMan software (V.5.3.5). If necessary, subgroup and sensitivity analysis will be performed. Grading of Recommendations Assessment, Development and Evaluation system will be used to assess the strength of evidence.Ethics and disseminationEthical approval is not necessary since no individual patient or privacy data have been collected. The results of this review will be disseminated in a peer-reviewed journal or an academic conference presentation.PROSPERO registration numberCRD42020190079.

Download Full-text

A comparison of clinical, radiographic and surgical outcomes of total hip arthroplasty between direct anterior and posterior approaches: a systematic review and meta-analysis

Hip International ◽

10.1177/1120700018820652 ◽

2018 ◽

Vol 29 (6) ◽

pp. 584-596 ◽

Cited By ~ 20

Author(s):

Fangteng Jia ◽

Bin Guo ◽

Feixiang Xu ◽

Yuechao Hou ◽

Xiongfeng Tang ◽

...

Keyword(s):

Systematic Review ◽

Total Hip Arthroplasty ◽

Hip Arthroplasty ◽

Meta Analysis ◽

Descriptive Analysis ◽

Direct Anterior Approach ◽

Efficacy And Safety ◽

Early Recovery ◽

Total Hip ◽

Number Of Patients

Objective: A systematic review and meta-analysis were used to directly evaluate the direct anterior approach (DAA) and the posterior approach (PA) for early efficacy and safety of total hip arthroplasty (THA). Methods: Control-led trials assessing DAA and PA for the efficacy and safety of THA were searched in the database. Articles were reviewed according to predetermined inclusion and exclusion criteria; the quality of the methodology included in a given study was strictly assessed before data extraction. Moreover, meta-analysis was performed for outcomes that can be combined; otherwise, descriptive analysis was performed. Results: There were 20 articles included, with a total of 7377 patients. Among these, 3728 and 3649 cases were in the DAA and PA groups, respectively. There was no difference between the DAA and PA groups at postoperative week 2 in the number of patients using the assistive ambulatory device or in time needed to completely discontinue all assistive ambulatory devices. Descriptive analysis found that DAA was slightly better than PA regarding early functional recovery and activity after surgery, as well as postoperative pain relief. Hospitalisation stay in the DAA group was shorter than in the PA group, in which the patients had a shorter operative time. Radiographic outcomes showed that there was little difference in prosthetic position between the DAA and PA groups. The proportions of intraoperative fractures and postoperative lateral cutaneous nerve of the thigh (LCNT) neuropraxia were significantly higher in the DAA group than in patients who underwent PA. Conclusion: Compared with PA, DAA presents superior early recovery following THA.

Download Full-text

Platelet transfusion for neonates with thrombocytopaenia: protocol for a systematic review

BMJ Open ◽

10.1136/bmjopen-2020-039132 ◽

2020 ◽

Vol 10 (10) ◽

pp. e039132

Author(s):

Dengjun Liu ◽

Jinlin Wu ◽

Tao Xiong ◽

Yan Yue ◽

Jun Tang

Keyword(s):

Systematic Review ◽

Evaluation System ◽

Platelet Transfusion ◽

Selection Process ◽

Data Extraction ◽

Meta Analysis ◽

Specific Treatment ◽

Cochrane Library ◽

Publication Date ◽

Case Control Studies

IntroductionThrombocytopaenia is one of the most common haemostatic abnormalities among neonates. It affects approximately one-quarter of neonates admitted into neonatal intensive care units and may lead to a high risk of bleeding and mortality, which are substantial causes for concern by neonatologists. Platelet transfusion (PT) is a specific treatment for thrombocytopaenia. To date, PT thresholds are diverse since the associations between low platelet count and negative outcomes are not clear. We propose this protocol for a systematic review to collect and assess evidence concerning the best PT threshold to reduce mortality, bleeding and major morbidity among neonates with thrombocytopaenia.Methods and analysisThe systematic review will be performed according to the Cochrane Handbook for Systematic Review of Interventions, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, and the Grading of Recommendations Assessment, Development and Evaluation system. Two independent researchers will perform the study selection, data extraction/coding, quality assessment and further analyses of the included studies, with disagreements being resolved by a third researcher. A systematic search of the literature will be conducted in the PubMed, Cochrane Library and Embase databases from database inception through 13 October 2020. All randomised controlled trials, cohort studies and case–control studies will be included without any restrictions regarding publication date or language. The primary outcomes will comprise in-hospital mortality and bleeding episodes. Endnote X9 and Review Manager V.5.3 software will be used to manage the selection process and statistical analysis, respectively. If the included studies are sufficient and homogeneous for any of the outcomes, a quantitative synthesis (meta-analysis) may be performed. Otherwise, we will conduct a narrative systematic review of the results.Ethics and disseminationEthical approval is not required for this study because the data will be obtained from published studies and will not include individual patient data. The results of this study are anticipated to be published in a peer-reviewed journal.PROSPERO registration numberCRD42020169262.

Download Full-text

Efficacy and Safety of Brucea javanica Oil Emulsion Injection for Treating Gastric Cancer: A Protocol for a Systematic Review and Meta Analysis

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2021/5236454 ◽

2021 ◽

Vol 2021 ◽

pp. 1-6

Author(s):

Luchang Cao ◽

Xinmiao Wang ◽

Heping Wang ◽

Jingyuan Wu ◽

Taicheng Lu ◽

...

Keyword(s):

Gastric Cancer ◽

Systematic Review ◽

Evaluation System ◽

Meta Analysis ◽

Performance Status ◽

Biomedical Literature ◽

Efficacy And Safety ◽

Oil Emulsion ◽

Brucea Javanica ◽

Brucea Javanica Oil

Introduction. Brucea javanica oil emulsion injection (BJOEI) is an antitumor drug extracted from the traditional Chinese medicinal plant Brucea javanica, which has broad prospects as an adjuvant treatment for gastric cancer (GC); however, its efficacy and safety are still controversial. We plan to conduct a systematic review and meta-analysis to summarise the clinical efficacy and safety of BJOEI in the treatment of GC and provide credible evidence for the clinical application and subsequent studies of BJOEI. Methods and Analysis. This systematic review will include articles identified by electronically searching the following databases: PubMed, EMBASE, CENTRAL, Web of Science, the Chinese Biomedical Literature Database (CBM), the China National Knowledge Infrastructure (CNKI), Wanfang Database, and Chinese Scientific Journals Database (VIP Database) from inception to 31 July 2021. The primary outcomes of this research will be the clinical total effective rate, performance status, and adverse drug reactions (ADRs). The systematic review will be performed using RevMan 5 software. Finally, we will use the Grading of Recommendations Assessment, Development and Evaluation System (GRADE) to assess the quality of evidence. Ethics and Dissemination. Ethical approval is not required for literature-based studies. The results of this systematic review will be published in a peer-reviewed journal. PROSPERO registration number: CRD42021265646.

Download Full-text